Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Increased Plasma Brain-Derived Neurotropic Factor, Not Nerve Growth Factor-Beta, in Schizophrenia Patients with Better Response to Risperidone Treatment

Authors
Lee, Bun-HeeKim, Yong-Ku
Issue Date
2009
Publisher
KARGER
Keywords
Brain-derived neurotropic factor; Nerve growth factor-beta; Risperidone; Schizophrenia
Citation
NEUROPSYCHOBIOLOGY, v.59, no.1, pp.51 - 58
Indexed
SCIE
SCOPUS
Journal Title
NEUROPSYCHOBIOLOGY
Volume
59
Number
1
Start Page
51
End Page
58
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/122130
DOI
10.1159/000205518
ISSN
0302-282X
Abstract
Background: Some neurotropins, including brain-derived neurotropic factor (BDNF) or nerve growth factor-beta (beta-NGF), play important roles in neurodevelopment and neuroprotection. We examined the plasma levels of these 2 factors in schizophrenia patients at the time of admission and after 6 weeks of treatment with risperidone. Methods: Plasma BDNF and beta-NGF levels were measured in 36 schizophrenia patients and 36 healthy controls. All the patients underwent 6 weeks of treatment with risperidone. The severity of schizophrenia and response to treatment were assessed with the positive and negative syndrome scale (PANSS). We compared plasma BDNF and beta-NGF levels among much-improved (n = 13, 36.1%, >= 50% PANSS score reduction), minimal-improved (n = 15, 41.7%, >= 25% and < 50% PANSS score reduction) and nonresponse patients (n = 8, 22.2%, < 25% PANSS score reduction). Results: At baseline, plasma BDNF had no significant difference between schizophrenia patients and controls, but beta-NGF levels were significantly lower in schizophrenia patients than controls (p = 0.037). Plasma BDNF and beta-NGF in all schizophrenia patients had no significant changes between pre- and posttreatment. Baseline BDNF levels were significantly lower in nonresponse patients than others (p = 0.038). After treatment, much-improved patients had significantly higher plasma BDNF than nonresponse patients (p = 0.023). However, beta-NGF levels had no significant differences between them. Conclusions: Our data suggest that higher plasma BDNF levels might be associated with better response to risperidone treatment, while plasma beta-NGF levels might have no effect on the clinical response in schizophrenia patients. Copyright (C) 2009 S. Karger AG, Basel
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Yong Ku photo

Kim, Yong Ku
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE